C4x Discovery Share Discussion Threads

[sbb1x] 14/1/2020 16:10

New 52 week low, what's the crack here....

[the stigologist] 13/1/2020 12:41

They've tweeted about being at #JMP20 #C4XD

[wigwammer] 13/1/2020 10:25

Punters still locking in losses - the last thing they will want is for this to gap upwards. Why did they buy in the first place? NRF2 and IL17 on track for outlicensing this year and the company is funded at least to that point. Bit daft to state the company is making "horrendous losses" - it is a developmental biotech company investing money to build valuable IP - of course it is going to show accounting losses :)

[trotterstrading] 10/1/2020 18:24

Preso and Webcast served up more of the same unfortunately. C4 Cash burn is absolutely horrendous. WTF have they been doing with all that cash for the past 2 years! Clearly the next two molecules off the rank (NRF2 and IL-17) require rework to get them to the point of out license. NRF2 has been the 'partnering' phase for 12 MONTHS!

[davemac3] 09/1/2020 21:53

Stig, that deal was based on milestone payments just as any deal with C4XD will be. I was talking about an upfront payment being double the market cap.

[the stigologist] 09/1/2020 18:28

IIRC IMM started to drop into 7s just before they signed a deal worth multiples of that market cap

[davemac3] 09/1/2020 17:01

£12k worth of shares traded and share price falls 7%!

Probably won't turn until a deal is signed or Directors buy. I still think the NRF-2 deal may be a few months away. The results indicated a candidate molecule for this project would be chosen in 1Q 2020 so we will probably have to wait for potential buyers to see the full data package for the molecule before committing. Meanwhile could be a chance to accumulate at a bargain price, if you believe the story.
The upfront payment for any deal could be double C4XD's market cap at this rate.

[davemac3] 07/1/2020 14:09

results presentation

[wigwammer] 07/1/2020 11:52

"Leading the wave is our NRF-2 programme for the treatment of inflammatory diseases where recently generated data will help to drive a competitive partnering process."

[wigwammer] 07/1/2020 11:51

As stigologist suggests, that is boilerplate stuff. I was surprised to see the stock lower this morning - there is going to be a competitive process for at least two of their assets, and the rhetoric in that regard appears to be getting more confident, not less. ATB :)

[davemac3] 07/1/2020 10:26

Diplomat -filtered for being a plonker

you said "no expectation"

the statement says

"The Board also have a reasonable expectation that a new licence deal will be signed during the 2020 calendar year"

[diplomat65] 07/1/2020 10:26

I still hold the 40,000 shares I bought last year at 60p so feeling somewhat bruised. I'm not selling, believing as I did last year in the strength of the Board and the business model. Just looking for pain relief this morning. . .

[the stigologist] 07/1/2020 10:10

That's standard boilerplate if you are used to reading such statements. Hope you weren't one of the muppet retail investors duped in the first hour.

[diplomat65] 07/1/2020 09:58

Have another read through Stigologist's useful summary of the RNS below - "no guarantee" being the operative statement.

[the stigologist] 07/1/2020 08:55

first hour is retail

[davemac3] 07/1/2020 08:33

I don' think it says that Diplomat....

[diplomat65] 07/1/2020 08:28

More positive news of the next commercial deal happening within the next 6 months would have qualified as a highlight. Instead we are told there can be no expectation of a further commercial deal been completed during the next 12 months.

[cantrememberthis2] 07/1/2020 08:03

Sub Cash Level 2 Weeks to Results
Possible 1x Bagger
Quick Summary here:

[the stigologist] 07/1/2020 07:59

LOL seen off

[pejaten] 07/1/2020 07:53

What did you expect? If you invested for something mature why not try Glaxo?

[diplomat65] 07/1/2020 07:38

HighlightsFinancial-- Revenue was GBPnil-- R&D expenses increased 51% to GBP10,585,000-- Total loss after tax was GBP10,912,000. . . and these are the highlights of 2019?

[pejaten] 07/1/2020 07:28

Depends on what your expectations are.

[the stigologist] 07/1/2020 07:27

"The Board also have a reasonable expectation that a new licence deal will be signed during the 2020 calendar year and that a further milestone payment on the Orexin-1 contract will be achieved within the forecast period, although there can be no guarantees that either of these events will occur, and they are not reflected in the Board's base case cash flow forecasts"

Base Case suggests cash runway to March 2021

[davemac3] 07/1/2020 07:20

Underwhelming